Literature DB >> 26743343

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation.

Anita D'Souza1, Jiaxing Huang2, Parameswaran Hari2.   

Abstract

Hematologic response criteria in light chain (AL) amyloidosis were updated in 2012 to incorporate free light chain responses. These criteria have been validated in autologous hematopoietic cell transplantation in AL at 6 and 12 months after transplantation. Using a transplantation registry, we assessed day 100 responses in AL amyloidosis. We validate the prognostic significance of the new criteria at this time point. Further, we show that patients who do not achieve at least a very good partial response by this time point have equally worse outcomes, regardless of depth of response (partial versus no response). Thus, we conclude that the new criteria help identify the poor responders by day 100 after transplantation and that this subset of patients should be studied for early evaluation in consolidation trials.
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2012 response criteria; Day 100 post-transplantation response; Light chain (AL) amyloidosis

Mesh:

Substances:

Year:  2015        PMID: 26743343      PMCID: PMC4801777          DOI: 10.1016/j.bbmt.2015.12.021

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  8 in total

1.  Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

Authors:  V Sanchorawala; D C Seldin; B Magnani; M Skinner; D G Wright
Journal:  Bone Marrow Transplant       Date:  2005-10       Impact factor: 5.483

2.  New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation.

Authors:  Saulius Girnius; David C Seldin; Maria Teresa Cibeira; Vaishali Sanchorawala
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

Review 3.  Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.

Authors:  R L Comenzo; D Reece; G Palladini; D Seldin; V Sanchorawala; H Landau; R Falk; K Wells; A Solomon; A Wechalekar; J Zonder; A Dispenzieri; M Gertz; H Streicher; M Skinner; R A Kyle; G Merlini
Journal:  Leukemia       Date:  2012-04-05       Impact factor: 11.528

4.  Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.

Authors:  Christopher P Venner; Julian D Gillmore; Sajitha Sachchithanantham; Shameem Mahmood; Thirusha Lane; Darren Foard; Murielle Roussel; Lisa Rannigan; Simon Dj Gibbs; Jennifer H Pinney; Carol J Whelan; Helen J Lachmann; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

5.  Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis.

Authors:  Jean D Sipe; Merrill D Benson; Joel N Buxbaum; Shu-ichi Ikeda; Giampaolo Merlini; Maria J M Saraiva; Per Westermark
Journal:  Amyloid       Date:  2014-09-29       Impact factor: 7.141

6.  Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.

Authors:  Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; Tow Tan; Shirshendu Sinha; Nelson Leung; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  Am J Hematol       Date:  2011-02-15       Impact factor: 10.047

7.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Authors:  Giovanni Palladini; Angela Dispenzieri; Morie A Gertz; Shaji Kumar; Ashutosh Wechalekar; Philip N Hawkins; Stefan Schönland; Ute Hegenbart; Raymond Comenzo; Efstathios Kastritis; Meletios A Dimopoulos; Arnaud Jaccard; Catherine Klersy; Giampaolo Merlini
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

8.  Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.

Authors:  M A Gertz; M Q Lacy; A Dispenzieri; S K Kumar; D Dingli; N Leung; W J Hogan; F K Buadi; S R Hayman
Journal:  Bone Marrow Transplant       Date:  2012-09-10       Impact factor: 5.483

  8 in total
  1 in total

1.  A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Authors:  Vaishali Sanchorawala; Giovanni Palladini; Vishal Kukreti; Jeffrey A Zonder; Adam D Cohen; David C Seldin; Angela Dispenzieri; Arnaud Jaccard; Stefan O Schönland; Deborah Berg; Huyuan Yang; Neeraj Gupta; Ai-Min Hui; Raymond L Comenzo; Giampaolo Merlini
Journal:  Blood       Date:  2017-05-26       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.